Considering that BRCA1-deficient cancer cells are hypersensitive to the inhibition of the BER component PARP1, we decided to analyse the potential therapeutic use of the OGG1 inhibitor TH5487 (22) specifically in the context of BRCA1 deficiency. Here, OGG1 is linked to cancer.